Ovarian Cancers : Advances through International Research Cooperation (GINECO, ENGOT, GCIG)

This book provides an overview of the latest developments in the concepts and management of ovarian cancer. The new data presented throughout opens the way to radically different therapeutic approaches. Surgery remains the core of ovarian cancer treatment, but its ultimate goal and the standard surg...

Full description

Saved in:
Bibliographic Details
Corporate Author: SpringerLink (Online service)
Other Authors: Pujade-Lauraine, Eric. (Editor), Ray-Coquard, Isabelle. (Editor), Lécuru, Fabrice. (Editor)
Format: eBook
Language: English
Published: Cham : Springer International Publishing : Imprint: Springer, 2017.
Subjects:
Medicine.
Gynecology.
Oncology.
Pathology.
Reproductive medicine.
Surgical oncology.
elektronické knihy
electronic books
ISBN: 9783319321103
Physical Description: X, 286 p. 12 illus., 9 illus. in color. online resource.

Cover

Table of contents

LEADER 04687nam a22004335i 4500
001 101513
003 CZ-ZlUTB
005 20240914113443.0
006 m o d
007 cr nn 008mamaa
008 161017s2017 gw | s |||| 0|eng d
020 |a 9783319321103 
024 7 |a 10.1007/978-3-319-32110-3  |2 doi 
245 1 0 |a Ovarian Cancers :  |b Advances through International Research Cooperation (GINECO, ENGOT, GCIG) /  |c edited by Eric Pujade-Lauraine, Isabelle Ray-Coquard, Fabrice Lécuru. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2017. 
300 |a X, 286 p. 12 illus., 9 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a počítač  |b c  |2 rdamedia 
338 |a online zdroj  |b cr  |2 rdacarrier 
505 0 |a Ovarian cancer management -- Clinical research in Europe dedicated to ovarian cancers -- Oncogenetics -- Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality -- How to evaluate tumor burden before therapeutic decision -- Value of lymphadenectomy -- HYPEC: what is the evidence? -- Onco-fertility applied to ovarian cancers -- First-line systemic therapy (chemo/antiangiogenics) -- Elderly -- Treatment at relapse (surgery & systemic treatments) -- How to evaluate QoL -- The future in ovarian cancers & place of the new immunotherapies in ovarian cancers -- Particular types of ovarian cancers -- High grade serous carcinoma & BRCA mutation anti-PARP -- Borderline and low grade carcinoma -- Clear Cell carcinoma -- Endometrioid carcinoma -- Mucinous carcinoma -- Carcinosarcoma -- Germ cell tumors -- Sex cord tumors -- Very rare ovarian malignant tumors including small cell carcinoma. Ovarian cancer management -- Clinical research in Europe dedicated to ovarian cancers -- Oncogenetics -- Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality -- How to evaluate tumor burden before therapeutic decision -- Value of lymphadenectomy -- HYPEC: what is the evidence? -- Onco-fertility applied to ovarian cancers -- First-line systemic therapy (chemo/antiangiogenics) -- Elderly -- Treatment at relapse (surgery & systemic treatments) -- How to evaluate QoL -- The future in ovarian cancers & place of the new immunotherapies in ovarian cancers -- Particular types of ovarian cancers -- High grade serous carcinoma & BRCA mutation anti-PARP -- Borderline and low grade carcinoma -- Clear Cell carcinoma -- Endometrioid carcinoma -- Mucinous carcinoma -- Carcinosarcoma -- Germ cell tumors -- Sex cord tumors -- Very rare ovarian malignant tumors including small cell carcinoma. 
506 |a Plný text je dostupný pouze z IP adres počítačů Univerzity Tomáše Bati ve Zlíně nebo vzdáleným přístupem pro zaměstnance a studenty 
520 |a This book provides an overview of the latest developments in the concepts and management of ovarian cancer. The new data presented throughout opens the way to radically different therapeutic approaches. Surgery remains the core of ovarian cancer treatment, but its ultimate goal and the standard surgical procedure have evolved, giving rise to the question of how to label expert centers for debulking surgery. Neo-adjuvant chemotherapy is becoming more popular and is also a new field for testing novel drug combinations. Over recent years, ovarian cancer management has embraced molecular biology. It is now more correct to talk about cancers of the ovary rather than ovarian cancer, since it is not a unique disease but several entities with different molecular drivers. The significant advances in drugs targeting the microenvironment or the tumor cell DNA repair mechanisms are presented in detail together with exciting future perspectives. All these advances would not have been possible without collaborative groups such as the GINECO group in France and their integration in wider clinical research networks at the European (ENGOT) and international (GCIG) level. 
650 0 |a Medicine. 
650 0 |a Gynecology. 
650 0 |a Oncology. 
650 0 |a Pathology. 
650 0 |a Reproductive medicine. 
650 0 |a Surgical oncology. 
655 7 |a elektronické knihy  |7 fd186907  |2 czenas 
655 9 |a electronic books  |2 eczenas 
700 1 |a Pujade-Lauraine, Eric.  |e editor. 
700 1 |a Ray-Coquard, Isabelle.  |e editor. 
700 1 |a Lécuru, Fabrice.  |e editor. 
710 2 |a SpringerLink (Online service) 
776 0 8 |i Printed edition:  |z 9783319321080 
856 4 0 |u https://proxy.k.utb.cz/login?url=http://dx.doi.org/10.1007/978-3-319-32110-3  |y Plný text 
992 |c NTK-SpringerMED 
999 |c 101513  |d 101513 
993 |x NEPOSILAT  |y EIZ 

Similar Items